Phaseline

Targets › SFTPD

SFTPD (Pulmonary surfactant-associated protein D): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Mar 2028.

Soluble pattern recognition receptor that functions in the innate immune response, acting at pulmonary and other mucosal surfaces, and plays diverse roles in immune regulation and antimicrobial defense. Binds and aggregates Gram-negative bacteria (E.coli), enhancing their uptake by immature dendritic cells (DCs) and also stimulates microbial antigen presentation by the DCs (By similarity). (UniProt, P35247)

Open in Phaseline: the race on SFTPD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Airway TherapeuticsZelpultide alfa
Recombinant human surfactant protein D (rhSP-D)
SFTPDPhase 2Bronchopulmonary DysplasiaMar 2028

Conditions

Bronchopulmonary Dysplasia (1)

Modalities

protein or peptide (1)

Companies

Airway Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.